Disk diffusion susceptibility testing for LY163892 (KT-3777), a new orally administered 1-carbacephem.
AUTOR(ES)
Jones, R N
RESUMO
LY163892, a new orally administered 1-carbacephem, was found to have a spectrum of antimicrobial activity very similar to that of cefaclor. Diffusion tests with 30-micrograms LY163892 disks produced acceptable interpretive error rates with greater than or equal to 22 mm as the susceptibility zone diameter. This was required to reduce potential false-susceptibility results, particularly among Enterobacter spp. and Providencia stuartii: both species included strains that produce beta-lactamases capable of hydrolyzing Ly163892. Preliminary recommendations for LY163892 disk tests are presented, but the continued use of the 30-micrograms cephalothin "class representative" disk might be the best procedure to minimize LY163892 interpretive errors for clinical trials. A separate LY163892 disk for testing Haemophilus influenzae strains should be seriously considered.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=266445Documentos Relacionados
- Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.
- Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin.
- Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.
- Pharmacokinetics of LY163892 in infants and children.
- Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.
